Skip to main content

Coronavirus (COVID-19): Latest Updates | Visitation PoliciesVisitation PoliciesVisitation PoliciesVisitation PoliciesVisitation Policies | COVID-19 Testing | Vaccine InformationVaccine InformationVaccine Information

menu

Ruth M. O'Regan, M.D.

Contact Information

Phone Numbers

Appointment: (585) 487-1700

Administrative: (585) 275-8538

Social Links

@oreganruth

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Locations

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box MED
Rochester, NY 14642

Faculty Appointments

Patient Care Setting

Cancer

Biography

Professional Background

Dr. Ruth O’Regan, M.D., is the Chair of Medicine and Charles A. Dewey Professor at the University of Rochester. She additionally serves as Physician-in-Chief of Strong Memorial Hospital and as Associate Director of Education and Mentoring at the Wilmot Cancer Institute at University of Rochester.

She previously was Division Chief of Hematology, Medical Oncology and Palliative Care in the Department of Medicine and as Deputy Director at the Carbone Cancer Center at the University of Wisconsin School of Medicine and Public Health (UWSMPH). She served as Chief Scientific officer of the Big Ten Cancer Research Consortium guiding the research and scientific mission of the consortium and as Vice-Chair of the National Comprehensive Cancer Network Board of Directors. Prior to joining the faculty at UWSMPH she was Director of the Glenn Family Breast Cancer Program at the Winship Cancer Institute and as Vice-Chair for Education and Director of the Hematology Oncology Fellowship program in the Department of Hematology and Medical Oncology at Emory University. She additionally served as Chief of Hematology and Medical Oncology at the Georgia Cancer Center for Excellence at Grady Memorial Hospital.

Dr. O’Regan earned her Medical Degree from University College, Dublin, Ireland and completed her Internal Medicine residency at the Medical College of Wisconsin and her Hematology/Oncology fellowship at Northwestern University.

Her research program focuses on identifying mechanisms of resistance to breast-cancer therapies and on the development of new therapies with a specific focus on triple negative breast cancer.

Credentials

Specialties

    Education

    1988
    MBBCH | University College Dublin (Republic of Ireland)

    Post-doctoral Training & Residency

    07/01/1998 - 06/30/1999
    Residency in Internal Medicine at McGaw Medical Center of Northwestern University

    07/01/1995 - 06/30/1998
    Fellowship in Hematology & Oncology at McGaw Medical Center of Northwestern University

    07/01/1994 - 06/30/1995
    Internship in Internal Medicine at Medical College of Wisconsin

    07/01/1992 - 06/30/1994
    Fellowship at Mater Misericordiae University Hospital (Ireland)

    07/01/1991 - 06/30/1992
    Fellowship in Internal Medicine at Mease Hospital Dunedin

    07/01/1988 - 06/30/1991
    Residency in Internal Medicine at Mater Misericordiae University Hospital (Ireland)

    VIEW ALL expand_more

    Clinical Trials

    An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in Triple Positive Breast Cancers Hoosier Cancer Research Network BRE17-141

    Lead Researcher: Ruth M O'Regan

    Patient will be treated with neratinib, an aromatase inhibitor and trastuzumab for 24 weeks prior to surgery, following an initial 3 weeks of neratinib alone, aromatase inhibitor alone or the combination of neratinib and an aromatase inhibitor. A breast biopsy will be performed prior to Day 1 of week 4 of treatment. Following surgery, patients will receive standard of care HER2-directed and endocrine therapy at the treating physician's discretion.

    View Study Details

    A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024,A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024

    Lead Researcher: Ruth M O'Regan

    This is an open label, multi-institutional, single arm phase II trial of ribociclib in combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization or blinding is involved.

    View Study Details

    Publications

    Journal Articles

    3/16/2021
    Tolaney SM, Kalinsky K, Kaklamani V, D'Adamo DR, Aktan G, Tsai ML, O'Regan RM, Kaufman PA, Wilks ST, Andreopoulou E, Patt DA, Yuan Y, Wang G, Savulsky C, Xing D, Kleynerman E, Karantza V, Diab S. "Eribulin Plus Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase 1b/2 Study." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2021 Mar 16; Epub 2021 Mar 16.

    10/2020
    Dudek AZ, Liu LC, Fischer JH, Wiley EL, Sachdev JC, Bleeker J, Hurley RW, Tonetti DA, Thatcher GRJ, Venuti RP, O'Regan RM. "Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy." Breast cancer research and treatment.. 2020 Oct; 183(3):617-627. Epub 2020 Jul 22.

    10/2020
    Zhao J, Meisel J, Guo Y, Nahta R, Hsieh KL, Peng L, Wei Z, O'Regan R, Li X. "Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+?and FOXP3+?immune cells in HER2-positive breast cancer treated with neoadjuvant therapies." Breast cancer research and treatment.. 2020 Oct; 183(3):599-606. Epub 2020 Jul 26.

    VIEW ALL PUBLICATIONS